Roche begins tender offer in Disetronic deal:
This article was originally published in Clinica
Executive Summary
Roche began its tender offer to the shareholders of Burgdorf, Switzerland-based insulin pump group Disetronic on March 24. It is offering SwFr670 ($479) and two Roche non-voting equity shares per Disetronic share in its acquisition bid, which was announced last month (see Clinica No 1045, p 1). The tender period is scheduled to end on April 28, but can be extended by Roche if necessary; at least 80% of Disetronic's shareholders must accept the offer for it to go ahead.